Purpose: This study aimed to evaluate the retinal blood vessel parameters and the foveal avascular zone (FAZ) area using optical coherence tomography angiography (OCTA) in patients with acromegaly in comparison with healthy controls.
Methods: A total of 45 patients with acromegaly and 45 healthy controls were included in this study. In all patients, the vessel density (VD) of the deep and superficial macular vascular networks and the foveal avascular zone (FAZ) were measured using OCTA. The correlation of insulin-like growth factor 1 (IGF-1) level and disease duration with deep macular VD and FAZ values was analyzed. All parameters were registered. Results were assessed and compared between the two groups.
Results: Deep macular plexus VD values were lower in patients with acromegaly compared to the control group. No significant differences in VD values in the superficial segment, except for that in the inferior parafovea ( = .01) were found between the two groups. Furthermore, patients with acromegaly showed enlargement in the superficial ( = .30) and deep FAZ areas ( < .001). IGF-1 level and disease duration showed a significant negative correlation with the deep whole image ( = -0.216, = .041, = -0.339, = .001, respectively), deep parafovea ( = -0.271, = .01; = -0.372, < .001, respectively), deep parafovea superior hemi ( = -0.342, = .001; = -0.350, = .001, respectively), deep parafovea temporal ( = -0.224, = .034; = -0.234, = .026, respectively), deep parafovea nasal ( = -0.320, = .002; = -0.361, < .001, respectively), and deep parafovea superior VD values ( = -0.293, = .005; = -0.307, = .003, respectively) and a significant positive correlation with the deep FAZ area values ( = 0.244, = .02; = 0.329, = .002, respectively).
Conclusion: VD values in the deep macular capillary plexus were lower in patients with acromegaly, and the superficial and deep FAZ area enlarged. Patients with acromegaly may have an increased risk of developing ocular vascular complications. OCTA can be used to evaluate retinal blood VD in patients with acromegaly.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/02713683.2021.1877311 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes following CyberKnife robotic radiosurgery for pituitary adenomas-a large single-centre study.
Ecancermedicalscience
November 2024
Cyberknife and Tomotherapy Center, Jinnah Postgraduate Medical Center (JPMC), Karachi 75510, Pakistan.
Introduction: The role of stereotactic radiosurgery (SRS) in pituitary adenomas (PAs) is evolving especially considering its safety. Existing literature is hampered by limited sample sizes and short-term follow-ups, impeding its preeminence in the clinical and radiological outcomes. We propose a comprehensive, single-centred study to evaluate the outcomes following CyberKnife stereotactic radiosurgery (CK SRS) for PAs in a larger patient population, incorporating meticulous clinical and radiological follow-up.
View Article and Find Full Text PDFBackground: Acromegaly, although rare, is associated with multiple manifestations and complications; its high morbidity and mortality makes it a challenge. Treatment involves surgery and pharmacological therapies, focusing on biochemical normalization. This study analyzes the biochemical control in Colombian patients with acromegaly, seeking to improve the understanding of the effects of treatments in the management of the disease.
View Article and Find Full Text PDFReal-Life Data on the Safety of Pasireotide in Acromegaly: Insights from EudraVigilance.
Pharmaceuticals (Basel)
December 2024
Preclinical Department, Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550169 Sibiu, Romania.
Background/objectives: Pasireotide (PAS) is a somatostatin receptor ligand (SRL) used to treat acromegaly, a chronic condition caused by excess growth hormone. While it offers significant benefits as a second-line treatment for uncontrolled acromegaly, its use raises major concerns due to hyperglycemic side effects and gastrointestinal issues, the latter being similar to those seen with first-generation SRLs. The aim of this study is to evaluate the real-world evidence on adverse drug reactions (ADRs) reported for PAS in the EudraVigilance database, in comparison to other established drug-based therapies for acromegaly.
View Article and Find Full Text PDFParaneoplastic endocrine syndromes: a contemporary overview.
Expert Rev Endocrinol Metab
January 2025
Carrera de Medicina Humana, Universidad Científica del Sur, Lima, Perú.
Introduction: Endocrine paraneoplastic syndromes (ePNS) are caused by malignant cells that induce hormonal alterations unrelated to the tissue of origin of the neoplasm. The aim of this manuscript is to review the pathophysiology, diagnosis, and treatment of endocrine paraneoplastic syndromes (ePNS).
Areas Covered: We searched the PubMed/Medline, Embase, and Scielo databases, including 96 articles.
Acromegaly: diagnostic challenges and individualized treatment.
Expert Rev Endocrinol Metab
January 2025
Department of Medicine, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, USA.
Introduction: Acromegaly is due in almost all cases to a GH-secreting pituitary tumor. GH and IGF-1 excesses lead to its multi-system clinical manifestations and comorbidities. Acromegaly is under-diagnosed and typically presents with advanced disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!